

## List of Figures

<b>Sr No.</b>	<b>Table no.</b>	<b>Title</b>	<b>Page no.</b>
1	Figure 1.1	<b>ICG cell mortality of IMI</b>	32
2	Figure 1.2	<b>ICG cell mortality of CZ</b>	32
3	Figure 1.3	<b>ICG cell mortality of MN</b>	33
5	Figure 1.4	<b>ICG cell mortality of PE</b>	33
7	Figure 1.5	<b>Cell viability at the Sub-lethal concentrations for all AGs</b>	35
8	Figure 1.6	<b>Depicts the level of pcna in ICG cells treated with sub-lethal concentrations of AGs</b>	37
9	Figure 1.7	<b>Depicts the level of cyclin A in ICG cells treated with sub-lethal concentrations of AGs</b>	38
10	Figure 1.8	<b>Depicts the level of cyclin E in ICG cells treated with sub-lethal concentrations of AGs</b>	39
11	Figure 2.1	<b>Alteration in Cell Morphology of ICG Cells on Exposure of AGs</b>	62
12	Figure 2.2	<b>Depicts DCF-DH staining for ROS Generation in ICG cell line after exposure of IMI and CZ with sub lethal concentrations</b>	64
13	Figure 2.3	<b>Depicts DCF-DH staining for ROS Generation in ICG cell line after exposure of MN and PE with sub-lethal concentrations</b>	65
14	Figure 2.4	<b>Depicts the result of DCFDA staining in ICG cells exposed to AGs</b>	66
15	Figure 2.5	<b>SOD level after treatment of AGs</b>	68
16	Figure 2.6	<b>Catalase activities after treatment of AGs</b>	68
17	Figure 2.7	<b>GSH level after treatment of AGs</b>	69
18	Figure 2.8	<b>LPO level after treatment of AGs</b>	69
19	Figure 2.9	<b>Depicts the results of Acridine orange/Ethidium bromide assay for sub-lethal concentrations of all AGs (IMI and CZ)</b>	70
20	Figure 2.10	<b>Depicts the results of Acridine orange/Ethidium bromide assay for sub-lethal concentrations of all AGs (MN and PE)</b>	71
21	Figure 2.11	<b>Depicts the result of AO/EB staining in ICG cells exposed to AGs</b>	72
22	Figure 2.12	<b>Flow cytometry dot plots with double Annexin V-FITC/PI staining for Apoptosis of ICG cells exposed to IMI</b>	73
23	Figure 2.13	<b>Flow cytometry dot plots with double Annexin V-FITC/PI staining for Apoptosis of ICG cells exposed to CZ</b>	74

24	Figure 2.14	<b>Flow cytometry dot plots with double Annexin V-FITC/PI staining for Apoptosis of ICG cells exposed to MN</b>	75
25	Figure 2.15	<b>Flow cytometry dot plots with double Annexin V-FITC/PI staining for Apoptosis of ICG cells exposed to PE</b>	76
26	Figure 2.16	<b>Depicts the results of summary data of FACs analysis of apoptosis for IMI</b>	77
27	Figure 2.17	<b>Depicts the results of summary data of FACs analysis of apoptosis for CZ</b>	77
28	Figure 2.18	<b>Depicts the results of summary data of FACs analysis of apoptosis for PE</b>	78
29	Figure 2.19	<b>Depicts the results of summary data of FACS analysis of apoptosis for MN</b>	78
30	Figure 2.20	<b>The level of bcl2 in ICG cells treated with sub-lethal concentrations of AGs</b>	81
31	Figure 2.21	<b>The level of caspase 3 in ICG cells treated with sub-lethal concentrations of AGs</b>	82
32	Figure 2.22	<b>The level of nfkb in ICG cells treated with sub-lethal concentrations of AGs</b>	83
33	Figure 2.23	<b>The level of bax in ICG cells treated with sub-lethal concentrations of AGs</b>	84
34	Figure 2.24	<b>The level of tnfa in ICG cells treated with sub-lethal concentrations of AGs</b>	85
34	Figure 3.1	<b>Depicts the results of DAPI staining with sub-lethal concentrations of all AGs</b>	108
35	Figure 3.2	<b>Different types of nucleus abnormalities A- micronucleus B-Bi-nucleated cells C- Lobbed Nucleated cells on exposure of 7 days of AGs</b>	109
36	Figure 3.3	<b>Depicts frequency micronuclei formation in ICG cells exposed to AGs.</b>	112
37	Figure 3.4	<b>Depicts frequency binucleated formation in ICG cells exposed to AGs.</b>	112
38	Figure 3.5	<b>Depicts frequency lobbed nuclei formation in ICG cells exposed to AGs.</b>	113
39	Figure 3.6	<b>Depicts the total nuclear abnormalities in ICG cells exposed to AGs. .</b>	113
40	Figure 3.7	<b>The level of p450 in ICG cells treated with sub-lethal concentrations of AGs</b>	114
41	Figure 3.8	<b>The level of dnmt in ICG cells treated with sub-lethal concentrations of AGs</b>	115
42	Figure 3.9	<b>Nucleotide sequence alignment of the dnmt region between nucleotide 21-134 of known sequence for dnmt for <i>C. catla</i> and cells treated with IMI</b>	117

43	Figure 3.10	<b>Nucleotide sequence alignment of the P450 region between nucleotide 104-235 and B) 297-424 of known sequence for p450 for <i>C. catla</i> and cells treated with IMI</b>	117
44	Figure 4.1	<b>Imidacloprid structure and Pie chart indicating Target proteins class distribution</b>	133
45	Figure 4.2	<b>Cymoxanil structure and Pie chart indicating Target proteins class distribution</b>	134
46	Figure 4.3	<b>Mancozeb structure and Pie chart indicating Target proteins class distribution</b>	135
47	Figure 4.4	<b>Pyrazosulfuron ethyl structure and Pie chart indicating Target proteins class distribution</b>	136
48	Figure 4.5	<b>Gene interaction of PCNA showing interaction with more than 10 genes</b>	140
49	Figure 4.6	<b>Gene interaction of CCNE1 showing interaction with more than 10 genes</b>	141
50	Figure 4.7	<b>Gene interaction of CCNA2 showing the overall interaction with 51 genes</b>	142
51	Figure 4.8	<b>Gene interaction of bax showing interaction with more than 10 genes</b>	143
52	Figure 4.9	<b>Gene interaction of bcl2 showing interaction with more than 10 genes</b>	143
53	Figure 4.10	<b>Gene interaction of casp3 showing interaction with more than 10 genes</b>	144
54	Figure 4.11	<b>Gene interaction of nfkb showing interaction with more than 10 genes</b>	144
55	Figure 4.12	<b>Gene interaction of tnfa showing interaction with more than 30 genes</b>	145
56	Figure GC	<b>Graphical Abstract</b>	150